Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study

BACKGROUND AND AIMS: At Saitama Medical Center, for remission induction in active ulcerative colitis (UC) patients with endoscopic evidence of severe disease, we tend to preferentially use tacrolimus (TAC) over anti-tumor necrosis factor (TNF)-α agents. We conducted this study to evaluate the validi...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Satohiro, Kawamura, Haruna, Nishikawa, Takeshi, Sagihara, Noriyoshi, Miyatani, Hiroyuki, Mashima, Hirosato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627753/
https://www.ncbi.nlm.nih.gov/pubmed/29026326
http://dx.doi.org/10.2147/CEG.S143224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627753/
https://www.ncbi.nlm.nih.gov/pubmed/29026326
http://dx.doi.org/10.2147/CEG.S143224

Ejemplares similares